Comparing the current results to its competitors, Tracon Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2024 year on year by -99.39 %, despite the revenue increase by the most of its competitors of 193.65 %, recorded in the same quarter.
Tracon Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment for the development and commercialization of new drugs, facing competitors with greater financial, technical, and human resources. Competitors also compete in recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may concentrate resources among fewer competitors. Smaller or early-stage companies may also be significant competitors, particularly through collaborations with larger companies. The company's commercial opportunities may be reduced or eliminated if competitors develop products that are more effective, safer, more convenient, or less expensive.
December 20, 2023
In recent updates, TRACON Pharmaceuticals has provided positive news regarding its ongoing ENVASARC pivotal Phase 2 trial. The company disclosed a significant increase in the Objective Response Rate (ORR) by investigator review, reaching 15% since the last interim analysis conducted in September. Despite this encouraging development, TRACON Pharmaceuticals reported a stagnant revenue growth in the second quarter of 2023, falling below the average revenue growth of its competitors.Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial:TRACON Pharmaceuticals is currently conducting a pivotal Phase 2 trial for its ENVASARC program. ENVASARC is a treatment developed to combat certain soft tissue sarcomas (STS...
Publicly Traded Peers of Tracon Pharmaceuticals Inc
Fate Therapeutics Inc Share Performance
-2.46%
Over The Past 5 Days
Fate Therapeutics Inc
Profile
Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.
Oncosec Medical Incorporated's business model revolves around developing and commercializing innovative immunotherapies for the treatment of various cancers.
Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Sources:
Tracon Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tracon Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
